文献速递消化道肿瘤放疗放疗物理与技术

MOREOVER:局部晚期直肠癌多组学MR引导放疗优化研究

MOREOVER: multiomics MR-guided radiotherapy optimization in locally advanced rectal cancer.
PubMed 文献 · Radiat Oncol · 2024-07-25

MOREOVER研究旨在将肠道微生物组和循环肿瘤DNA(ctDNA)基因组学信息整合到THUNDER-2试验的影像组学模型中,以提高局部晚期直肠癌(LARC)患者新辅助放化疗(nCRT)后病理完全缓解(pCR)的预测能力。研究在7个时间点纵向采集ctDNA、微生物组和基因组学数据,按TRIPOD声明进行建模,构建多组学决策支持系统以实现个体化治疗。

要点

  • 将肠道微生物组与ctDNA组学信息纳入影像组学模型,以期提高pCR预测能力。
  • 在nCRT前、nCRT期间每周及手术前共7个时间点纵向采集组学数据。
  • 期望发现pCR组与非pCR组在粪便微生物组、ctDNA和影像组学特征上的差异。

核心结论

  • 将复合生物标志物与THUNDER-2试验所用影像组学模型整合,预期可提高该模型对pCR的预测能力。
  • 可操作的组学变量可能揭示与影像组学此前未知的相关性,为更精准全面的个体化治疗铺路。
  • 预期发现pCR组与非pCR组在粪便微生物组、ctDNA和影像组学特征上存在差异。
  • 预期发现所考虑组学特征的稳定性随时间存在变异性。
  • 所识别的特征将纳入专门建模方案,构建多组学决策支持系统以实现个体化治疗。

研究设计与样本

  • MOREOVER项目为对II期THUNDER-2试验(NCT04815694)的组学信息扩充研究。
  • 在7个时间点纵向分析ctDNA基因组学、微生物组和基因组学数据:nCRT前、nCRT期间每周一次及手术前。
  • 按TRIPOD声明对所采集数据进行专门建模。
  • 总体思路为将影像组学、宏基因组学、代谢组学、宏转录组学、人类基因组学和ctDNA通过整合多组学方法进行挖掘与组合。

主要发现

  • 研究为方案性描述,未报告实际分析结果。
  • 研究设定的预期包括pCR组与非pCR组间粪便微生物组、ctDNA和影像组学谱存在差异。
  • 研究设定的预期还包括所考虑组学特征的稳定性随时间存在变异性。

关键数值与推荐

  • 研究在nCRT前、nCRT期间每周一次及手术前共7个时间点采集并分析纵向ctDNA基因组学、微生物组和基因组学数据。
  • 复合生物标志物与影像组学模型的整合以THUNDER-2试验所用模型为基础。
  • 建模依据TRIPOD声明进行。

临床怎么用

  • 原文未据此给出推荐。
  • 研究旨在描述与nCRT耐药相关的纵向微生物组数据,并提出未来在治疗类型和时机方面的治疗策略设想,如对无应答患者行粪便微生物移植。
  • 研究旨在描述nCRT全程的基因组学模式和ctDNA数据演变,以支持预测结局并识别新的风险分层因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complete response prediction in locally advanced rectal cancer (LARC) patients is generally focused on the radiomics analysis of staging MRI. Until now, omics information extracted from gut microbiota and circulating tumor DNA (ctDNA) have not been integrated in composite biomarkers-based models, thereby omitting valuable information from the decision-making process. In this study, we aim to integrate radiomics with gut microbiota and ctDNA-based genomics tracking during neoadjuvant chemoradiotherapy (nCRT). METHODS: The main hypothesis of the MOREOVER study is that the incorporation of composite biomarkers with radiomics-based models used in the THUNDER-2 trial will improve the pathological complete response (pCR) predictive power of such models, paving the way for more accurate and comprehensive personalized treatment approaches. This is due to the inclusion of actionable omics variables that may disclose previously unknown correlations with radiomics. Aims of this study are: - to generate longitudinal microbiome data linked to disease resistance to nCRT and postulate future therapeutic strategies in terms of both type of treatment and timing, such as fecal microbiota transplant in non-responding patients. - to describe the genomics pattern and ctDNA data evolution throughout the nCRT treatment in order to support the prediction outcome and identify new risk-category stratification agents. - to mine and combine collected data through integrated multi-omics approaches (radiomics, metagenomics, metabolomics, metatranscriptomics, human genomics, ctDNA) in order to increase the performance of the radiomics-based response predictive model for LARC patients undergoing nCRT on MR-Linac. EXPERIMENTAL DESIGN: The objective of the MOREOVER project is to enrich the phase II THUNDER-2 trial (NCT04815694) with gut microbiota and ctDNA omics information, by exploring the possibility to enhance predictive performance of the developed model. Longitudinal ctDNA genomics, microbiome and genomics data will be analyzed on 7 timepoints: prior to nCRT, during nCRT on a weekly basis and prior to surgery. Specific modelling will be performed for data harvested, according to the TRIPOD statements. DISCUSSION: We expect to find differences in fecal microbiome, ctDNA and radiomics profiles between the two groups of patients (pCR and not pCR). In addition, we expect to find a variability in the stability of the considered omics features over time. The identified profiles will be inserted into dedicated modelling solutions to set up a multiomics decision support system able to achieve personalized treatments.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Boldrini L, Chiloiro G, Di Franco S, et al. MOREOVER: multiomics MR-guided radiotherapy optimization in locally advanced rectal cancer. Radiat Oncol. 2024. PMID: 39054479. doi:10.1186/s13014-024-02492-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。